ArrowMark Colorado Holdings discloses 4.26% TNDM stake in 13G/A filing
Rhea-AI Filing Summary
ArrowMark Colorado Holdings, LLC filed an amended Schedule 13G to report its passive ownership in DIABETES CARE INC common stock. As of the event date of 12/31/2025, ArrowMark reported beneficial ownership of 2,889,691 shares, representing 4.26% of the outstanding common stock.
ArrowMark, a Delaware entity, disclosed sole voting and dispositive power over all of these shares and no shared power with other parties. It certified that the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the company.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does ArrowMark’s Schedule 13G/A filing for TNDM report?
The filing reports that ArrowMark Colorado Holdings, LLC beneficially owns 2,889,691 shares of DIABETES CARE INC common stock, equal to 4.26% of the class as of December 31, 2025, and holds these shares on a passive, non‑control basis.
How large is ArrowMark’s ownership stake in TNDM?
ArrowMark reported beneficial ownership of 2,889,691 shares of DIABETES CARE INC common stock, representing 4.26% of the outstanding class as of December 31, 2025. This places its stake below the 5% threshold typically associated with larger reporting shareholders.
Is ArrowMark’s TNDM position intended to influence control of the company?
No. ArrowMark certified the DIABETES CARE INC shares were acquired and are held in the ordinary course of business, not to change or influence control of the issuer, and not in connection with any transaction designed to have that effect, consistent with passive ownership reporting.
Why is this TNDM filing labeled as Schedule 13G/A Amendment No. 1?
The designation Schedule 13G/A Amendment No. 1 indicates ArrowMark is updating a previously filed beneficial ownership report. This amendment refreshes its disclosed holdings, showing a 4.26% stake in DIABETES CARE INC common stock as of December 31, 2025.
Who signed the Schedule 13G/A filed for TNDM on behalf of ArrowMark?
The filing was signed by Richard Grove, Chief Compliance Officer of ArrowMark Colorado Holdings, LLC. By signing, he certified that the information regarding DIABETES CARE INC share ownership is true, complete, and correct to the best of his knowledge and belief.